$GH

Kalia Kumud purchased $78K of GH

Kalia Kumud (Chief Information Officer) purchased 600 shares of Guardant Health, Inc. (GH) at $130.76 on 2026-06-15.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 30, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Bullish
medium confidence
Mentioned
$GH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHBullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase by the company’s CIO, which may slightly influence sentiment but is not a fundamental update.

02

Market read

Traders may note the insider buy as a small positive sentiment datapoint, but it is unlikely to drive a major repricing alone.

03

What to watch

The filing does not indicate intent beyond the disclosed buy; without follow-on buys/sells or a larger transaction size, signal strength is limited.

Relevance 4/10Novelty 5/10Timing: new Form 4 filed 2026-06-30 (covers 2026-06-15 purchase)

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHBullishMedium confidence
Context

Guardant Health CIO Kalia Kumud filed a Form 4 open-market purchase of 600 shares at $130.76 on 2026-06-15.

Expected impact

Likely limited near-term impact; any reaction would be small and short-lived unless followed by additional disclosures.

Evidence & confidence

The transaction is a routine officer open-market buy (no 10b5-1 plan), but the dollar size (~$78k) is not large enough to be a standalone catalyst.

Market effects

No direct sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Officer purchases can be driven by personal liquidity needs, diversification, or routine compensation-related activity rather than a strong forward view.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Kalia Kumud

    Chief Information Officer who purchased 600 shares open-market at $130.76.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.